Review
Nature Reviews Cancer 5, 845-856 (November 2005) | doi:10.1038/nrc1739
Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Joseph A. Ludwig1,2 & John N. Weinstein1 About the authors
Abstract
Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the time of diagnosis could improve patient care. However, translation from bench to bedside outside of the research setting has proved more difficult than might have been expected. Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality.
- View At a Glance
Author affiliations
- Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
- Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Correspondence to: John N. Weinstein1 Email: weinstein@dtpax2.ncifcrf.gov
Published online 20 October 2005
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Sox2 is required for sensory organ development in the mammalian inner earNature Letters to Editor (21 Apr 2005)
